Truist lowered the firm’s price target on Vital Energy (VTLE) to $47 from $49 but keeps a Buy rating on the shares after its Q4 revenue miss.

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by Royal Bank of Canada from $402.00 to $407.00 in a research note issued to investors on Tuesday,Benzinga reports.

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

One headwind that could slow the uptake of the Vertex pain drug, though, is cost. The list price is $15.50 per pill ... opioid if given the choice. Vertex stock today trades for about 24x forward ...

Vertex's stock price has shown resilience, with a year-to-date performance of +22% as of September 2024. This growth has positioned the company as a potential value name in the biotech sector, ...

Morgan Stanley upped their target price on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th.

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a ... That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about ...

With multiple ongoing clinical trials and a robust pipeline, Vertex is poised to exceed conservative analyst revenue projections, making the stock a STRONG BUY with a 12-month price of $550/share.